SGI
ACAD icon

Summit Global Investments’s Acadia Pharmaceuticals ACAD Stock Holding History

Summit Global Investments’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-10,751
Closed -$232K – 464
2025
Q2 		$232K Sell
10,751
-13,183
-55% -$245K 0.01% 423
2025
Q1 		$398K Buy
+23,934
New +$435K 0.03% 327

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Summit Global Investments's ACAD Position: Q3 2025 in Review

Summit Global Investments sold out of Acadia Pharmaceuticals (ACAD) in Q3 2025, closing a stake of 10,751 shares — an estimated $232K sold.

Summit Global Investments first reported a position in ACAD in Q1 2025 and held it in 2 quarters. The position peaked at $398K in Q1 2025. 333 funds tracked by Wall St. Rank hold ACAD as of Q3 2025.

  • Summit Global Investments reported no remaining Acadia Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Summit Global Investments sold 10,751 Acadia Pharmaceuticals shares in Q3 2025, an estimated $232K.
  • Summit Global Investments first reported a position in Acadia Pharmaceuticals in Q1 2025 and held it in 2 quarters.
  • Summit Global Investments's Acadia Pharmaceuticals position peaked at $398K in Q1 2025.
  • 333 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2025.

Based on Summit Global Investments's 13F filing for Q3 2025, filed 3 Nov 2025.